Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts

Christopher Molvar*, Robert Lewandowski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatocellular carcinoma (HCC) is a lethal tumor, claiming over half a million lives per year. Treatment of HCC is commonly performed without curative intent, and palliative options dominate, including catheter-based therapies, namely, transarterial chemoembolization and yttrium-90 (90Y) radioembolization. This review will showcase the performance of 90Y radioembolization for the treatment of HCC, focusing on recent seminal data and technical advances. In particular, novel radioembolization treatment concepts are discussed and compared with conventional HCC therapy.

Original languageEnglish (US)
Pages (from-to)388-397
Number of pages10
JournalSeminars in Interventional Radiology
Volume32
Issue number4
DOIs
StatePublished - Dec 1 2015

Keywords

  • hepatocellular carcinoma
  • interventional radiology
  • liver cancer
  • radioembolization
  • therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts'. Together they form a unique fingerprint.

Cite this